# Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

> **NCT05626257** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 135 (actual)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **OTHER:** Xolair

## Key facts

- **NCT ID:** NCT05626257
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-12
- **Primary completion:** 2025-04-15
- **Final completion:** 2025-04-15
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626257, "Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05626257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*